Search and analyze individual stocks with comprehensive metrics
Brooks Laboratories Ltd
Fundamental Score
Brooks Laboratories Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of BROOKS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 21.24 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (301.52%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Conservative Debt Levels (D/E: 0.07)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (13.63x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (52.62%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
7 factors identified
Below-Average Return on Equity (-12.21%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-9.93%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-17.61%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Negative Free Cash Flow (₹-86.78 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Brooks Laboratories Ltd
About BROOKS
Business Overview
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Company Details
Key Leadership
Latest News
BROOKS Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Brooks Laboratories Ltd (BROOKS)?
As of 16 Jan 2026, 10:12 am IST, Brooks Laboratories Ltd (BROOKS) is currently trading at ₹68.35. The stock has a market capitalization of ₹296.77 (Cr).
Is BROOKS share price Overvalued or Undervalued?
BROOKS is currently trading at a P/E ratio of 21.24x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Brooks Laboratories Ltd share price?
Key factors influencing BROOKS's price include its quarterly earnings growth (Sales Growth: 12.79%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Brooks Laboratories Ltd a good stock for long-term investment?
Brooks Laboratories Ltd shows a 5-year Profit Growth of N/A% and an ROE of -12.21%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.07 before investing.
How does Brooks Laboratories Ltd compare with its industry peers?
Brooks Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare BROOKS's P/E of 21.24x and ROE of -12.21% against the industry averages to determine its competitive standing.
What is the P/E ratio of BROOKS and what does it mean?
BROOKS has a P/E ratio of 21.24x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹21 for every ₹1 of annual earnings.
How is BROOKS performing according to Bull Run's analysis?
BROOKS has a Bull Run fundamental score of 32/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does BROOKS belong to?
BROOKS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Brooks Laboratories Ltd.
What is Return on Equity (ROE) and why is it important for BROOKS?
BROOKS has an ROE of -12.21%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Brooks Laboratories Ltd generates profits from shareholders' equity.
How is BROOKS's debt-to-equity ratio and what does it indicate?
BROOKS has a debt-to-equity ratio of 0.07, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is BROOKS's dividend yield and is it a good dividend stock?
BROOKS offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has BROOKS grown over the past 5 years?
BROOKS has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in BROOKS and why does it matter?
Promoters hold 52.62% of BROOKS shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is BROOKS's market capitalization category?
BROOKS has a market capitalization of ₹297 crores, placing it in the Small-cap category.
How volatile is BROOKS stock?
BROOKS has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for BROOKS?
BROOKS has a 52-week high of ₹N/A and low of ₹N/A.
What is BROOKS's operating profit margin trend?
BROOKS has a 5-year average Operating Profit Margin (OPM) of -17.61%, indicating the company's operational efficiency.
How is BROOKS's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 12.79% and YoY Profit Growth of 301.52%.
What is the institutional holding pattern in BROOKS?
BROOKS has FII holding of 0.01% and DII holding of 10.38%. Significant institutional holding often suggests professional confidence in the stock.